Develops targeted alpha therapies (TAT) for treating cancer using alpha-emitting radioisotopes.
Xilio Therapeutics, Inc., a clinical-stage biotechnology firm based in Waltham, Massachusetts, focuses on advancing immunotherapies designed to bolster the immune response in cancer patients. Central to its portfolio is the checkpoint inhibitor program, highlighted by XTX101, a novel anti-CTLA-4 monoclonal antibody currently undergoing Phase 1/2 clinical trials in patients with various solid tumors. This therapy aims to enhance immune surveillance and promote targeted tumor cell destruction.
In addition to its checkpoint inhibitor endeavors, Xilio Therapeutics is actively developing cytokine programs aimed at harnessing the therapeutic potential of immune-modulating proteins. Among these programs is XTX202, a modified version of IL-2 designed to enhance efficacy while minimizing systemic toxicity. The company also pursues XTX301 and XTX401, novel IL-12 and IL-15 product candidates respectively, which utilize innovative masking techniques to activate specifically within the tumor microenvironment upon protease cleavage.
Founded in 2016, Xilio Therapeutics operates at the frontier of biopharmaceutical innovation, driven by a commitment to advancing treatment options for cancer patients. By strategically targeting immune checkpoints and leveraging cytokine biology, the company aims to redefine standards of care in oncology, offering new hope to those facing challenging diagnoses.